Vedanta’s Q3 profit jump 58% to Rs 4,224 crore on higher realisation
Its total income during the October-December quarter rose to Rs 23,621 crore from Rs 22,007 crore in the year-ago period, the filing said.
Strides Pharma Science on Thursday posted 68.8 per cent decline in consolidated profit at Rs 92.33 crore for the quarter ended December 31, 2019.
The drug firm had posted consolidated profit of Rs 296.43 crore in the year-ago period, Strides Pharma Science said in a regulatory filing. However, the consolidated income of the company increased to Rs 744.66 crore in the October-December period, as against Rs 579.54 crore a year ago.
Advertisement
“Our contrarian strategies continue to play out for the regulated markets, which are now delivering growth with industry-leading post research and development (R&D) EBITDA margins,” Strides Pharma Science founder Arun Kumar said.
Advertisement
Earnings before interest, tax, depreciation and amortization (EBITDA) is a measure of a company’s operating performance.
Kumar further noted that “while we are clearly tracking ahead of our plans for the regulated markets, the emerging markets are still a few quarters behind from demonstrating an improved performance anticipated by the strategic actions undertaken by the company to improve its quality of business”.
Shares of Strides Pharma Science were trading at Rs 468.60 a piece on BSE, up 4.86 per cent from the previous close. And on Nifty Rs 462.80 a piece up 3.56 per cent.
(With input from agencies)
Advertisement
Related posts
Dalal Street turns red; Sensex plunges 468 points, Nifty down to 13,839.00
In the broader markets, the S&P BSE MidCap and SmallCap also traded lower by 0.14 and 0.50 per cent respectively.
UltraTech Cement shares soar on strong Q3 earnings
Company's total expenses were at Rs 10,190.03 crore in the third quarter of financial year 2020-21.
